Iganidipine
Alternative Names: NKY 722Latest Information Update: 21 Sep 2010
At a glance
- Originator Kyoto Pharmaceutical Industries; Senju Pharmaceutical
- Developer ISTA Pharmaceuticals
- Class Antihypertensives; Piperazines; Pyridines
- Mechanism of Action Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Glaucoma
Most Recent Events
- 21 Sep 2010 Discontinued - Phase-I for Glaucoma in USA (Ophthalmic)
- 14 May 2009 Phase I development is ongoing in USA
- 21 Jun 2006 Iganidipine has been licensed to ISTA Pharmaceuticals in North America